Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Kidney Dis. 2009 Sep;54(3):440-9. doi: 10.1053/j.ajkd.2009.05.013. Epub 2009 Jul 23.

Homocysteine lowering and cognition in CKD: the Veterans Affairs homocysteine study.

Author information

  • 1Geriatric Research, Education, and Clinical Center, Veterans Affairs Boston Healthcare System, Boston, MA 02130, USA. cbbrady@bu.edu

Abstract

BACKGROUND:

Individuals with advanced chronic kidney disease (CKD) and end-stage renal disease (ESRD) have high plasma total homocysteine (tHcy) levels, which may be a risk factor for cognitive impairment. Whether treatment with high-dose B vitamins to decrease high tHcy levels improves cognition in persons with kidney disease is unknown.

STUDY DESIGN:

Randomized controlled trial.

SETTING & PARTICIPANTS:

A substudy of 659 patients (mean age, 67.3 +/- 11.7 years) who participated in a randomized double-blind clinical trial 5 years in duration conducted in 36 US Department of Veterans Affairs medical centers of the effect on all-cause mortality of vitamin-induced lowering of plasma tHcy level. 236 (35.8%) were treated by using dialysis (ESRD) and 423 (64.2%) had a Cockcroft-Gault estimated creatinine clearance of 30 mL/min or less (advanced CKD). All had high tHcy levels (> or =15 micromol/L) at baseline. Cognitive assessments began during the follow-up period of the main trial 3 years after treatment began; participants subsequently were retested 1 year later to assess cognitive change.

INTERVENTION:

Daily high-dose B vitamin capsule (40 mg of folic acid, 100 mg of vitamin B(6), and 2 mg of vitamin B(12)) or placebo.

OUTCOMES:

Cognitive function at initial assessment and 1 year later.

MEASUREMENTS:

Telephone Interview of Cognitive Status-modified, supplemented with attention, working memory, and executive function tests.

RESULTS:

Initial cognitive function was impaired in approximately 19% of patients regardless of treatment assignment (vitamin or placebo) or kidney disease status (advanced CKD or ESRD). Treatment decreased tHcy levels by 26.7%. Unadjusted and adjusted analyses showed that treatment did not improve initial cognitive outcomes or affect subsequent cognitive status 1 year later.

LIMITATIONS:

Cognitive assessments began after treatment was initiated; cognitive assessment was limited.

CONCLUSION:

Treatment with high daily doses of B vitamins, which decreased tHcy levels, did not affect cognitive outcomes in patients with advanced CKD and ESRD.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00032435 NCT00032435.

PMID:
19628319
PMCID:
PMC2748786
DOI:
10.1053/j.ajkd.2009.05.013
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center